Results 21 to 30 of about 35,539 (289)

Measles Virus Neutralizing Antibody Response, Cell-Mediated Immunity, and Immunoglobulin G Antibody Avidity Before and After Receipt of a Third Dose of Measles, Mumps, and Rubella Vaccine in Young Adults [PDF]

Journal of Infectious Diseases, 2015
BACKGROUND Two doses of measles, mumps, and rubella (MMR) vaccine are 97% effective against measles, but waning antibody immunity to measles and failure of the 2-dose vaccine occur.
Amy Parker Fiebelkorn, Laura A. Coleman, Edward A. Belongia, Sandra K. Freeman, Daphne York, Daoling Bi, Ashwin Kulkarni, Susette Audet, Sara Mercader, Marcia McGrew, Carole J. Hickman, William J. Bellini, Rupak Shivakoti, Diane E. Griffin, Judith Beeler   +14 more
openalex   +2 more sources

Humoral Immunity to Measles, Mumps, Rubella, Diphtheria, Tetanus and Pertussis After Cancer Treatment in Children [PDF]

Cancer Reports, Volume 8, Issue 5, May 2025.
ABSTRACT Background Treatment for pediatric malignancies has distinct effects on the immune system. Aims Our aim was to measure humoral immunity to measles, mumps and rubella (MMR), and diphtheria, tetanus and acellular pertussis (DTaP) vaccines after pediatric cancer treatment.
Susanna Sundell, Miia Laine, Liisa Järvelä, Ville Peltola, Tytti Vuorinen, Päivi Lähteenmäki, Linnea Schuez‐Havupalo   +6 more
wiley   +2 more sources

Comparative analysis of immunogenicity between first-dose measles-mumps-rubella (MMR) vaccine administration and combined MMR-rotavirus vaccination [PDF]

Human Vaccines & Immunotherapeutics
This study compared the immunogenicity of the measles-mumps-rubella (MMR) vaccine when administered alone versus when co-administered with the rotavirus vaccine in infants aged 8–9 months.
Xue-Feng Liang, Xiao-Shu Zhang, Jing An, Yu Tang   +3 more
doaj   +2 more sources

Efficacy of Intralesional Measles Mumps Rubella Vaccine in the Treatment of Verruca Vulgaris: An Interventional Study. [PDF]

Cureus, 2023
Surani AS, Un R, Marfatia Y.
europepmc   +3 more sources

MMR (measles-mumps-rubella) vaccine [PDF]

Paediatrics & Child Health, 2001
openaire   +3 more sources

Determination of ELISA reactive mumps IgG antibodies in MMR vaccine recipients in comparison with MMR vaccine naive children: A cross sectional study [PDF]

Scripta Medica, 2021
Background/Aim: Mumps is by vaccine preventable infectious disease characterised by parotitis. In India mumps vaccines are not currently used under National Immunisation Programme (NIP).
Gupta Riya, Saxena Naveen, Gupta Parul
doaj   +1 more source

Measles, mumps, rubella (MMR) vaccine [PDF]

Ceylon Medical Journal, 2011
SP Lamabadusuriya
openaire   +4 more sources

Safety and immunological effectiveness of the domestic combined trivaccine for the prevention of measles, rubella and mumps Vaktrivir^® in children 12 months and 6 years of age (results of a simple blind multicenter comparative randomized clinical trial)

Эпидемиология и вакцинопрофилактика, 2021
Relevanc. Measles, mumps and rubella, despite many years of vaccination, retain their epidemiological and social significance at the present time. The aim of the work is to study the safety and immunogenicity. Of the vaccine for the prevention of measles,
I. V. Feldblium, V. V. Romanenko, K. A. Subbotina, M. G. Menshikova, I. A. Okuneva, A. Y. Musikhina, T. E. Snitkovskaya, N. I. Marcovich, A. E. Ershov, D. M. Trofimov   +9 more
doaj   +1 more source

Parotitis Cases Due to Measles-Mumps-Rubella Vaccine [PDF]

Klimik Dergisi/Klimik Journal, 2010
Oral Oncul, Vedat Turhan, Ercan Yenilmez, Levent Gorenek, Saban Cavuslu, Ali Acar   +5 more
openaire   +3 more sources

A Review on Rubella Vaccine: Iran (1975-2019) [PDF]

Archives of Razi Institute, 2021
The first Attenuated rubella vaccine was developed by Parkman and Meyer in 1966. Ten years later in the 1975s, the rubella vaccine was developed in Razi Vaccine and serum research institute) RVSRI).
A Shafayi, A Mohammadi
doaj   +1 more source